MarketPeel
Insider Trading Intelligence
CV

Coelho Rogerio Vivaldi

CRNX
DIRECTOR · CRINETICS PHARMACEUTICALS, INC. · CIK 0001610381
FILING MIX · LIFETIME73%/27%
BUYS
19
SELLS
7
TOTAL VALUE
$411.1K
COMPANIES
2
ACTIVE SINCE
Jan 2022
HOLDINGS NOW
64,576
AVG SELL PX
$37.60
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Coelho Rogerio Vivaldi, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%-3.07%+0.42%-3.49%-0.95%
14d3+66.67%-5.48%-1.40%-4.08%+2.60%
30d3+0.00%+0.37%+2.20%-1.83%+6.01%
60d3+0.00%-5.94%+9.14%-15.07%-10.89%
90d3+66.67%-13.70%+8.56%-22.26%-18.96%
180d3(2 pending)+100.00%+52.55%+7.17%+45.38%+45.38%
1y3(2 pending)+100.00%+103.60%+26.24%+77.36%+77.36%
2y3(2 pending)+100.00%+50.32%+43.44%+6.88%+6.88%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRNX · 19,225 shares · as of Jul 2, 2026
08,75017,50026,25035,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 19 buys / 7 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,000$40.00$120.0K19,225Jul 2, 2026Jul 7, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,7309,730Jun 18, 2026Jun 22, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,92522,225Jun 18, 2026Jun 22, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
523$36.77$19.2K16,300Mar 12, 2026Mar 13, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,477$36.08$161.5K16,823Mar 12, 2026Mar 13, 2026View →
VTRS
VIATRIS INC
PURCHASE
1,17546,526Mar 6, 2026Mar 10, 2026View →
VTRS
VIATRIS INC
SALE
23,6600Mar 6, 2026Mar 10, 2026View →
VTRS
VIATRIS INC
SALE
1,174.4920Mar 6, 2026Mar 10, 2026View →
VTRS
VIATRIS INC
PURCHASEGRANT
Stock grant
15,89015,890Mar 6, 2026Mar 10, 2026View →
VTRS
VIATRIS INC
PURCHASE
23,66045,351Mar 6, 2026Mar 10, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,35010,350Jun 11, 2025Jun 13, 2025View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,90021,300Jun 11, 2025Jun 13, 2025View →
VTRS
VIATRIS INC
PURCHASEGRANT
Stock grant
23,66023,660Mar 6, 2025Mar 10, 2025View →
VTRS
VIATRIS INC
PURCHASE
21,26721,267Mar 4, 2025Mar 5, 2025View →
VTRS
VIATRIS INC
SALE
21,2670Mar 4, 2025Mar 5, 2025View →
VTRS
VIATRIS INC
SALE
423.0130Mar 4, 2025Mar 5, 2025View →
VTRS
VIATRIS INC
PURCHASE
42421,691Mar 4, 2025Mar 5, 2025View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,40014,400Jun 7, 2024Jun 11, 2024View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,50012,500Jun 7, 2024Jun 11, 2024View →
VTRS
VIATRIS INC
PURCHASEGRANT
Stock grant
21,26721,267Jun 3, 2024Jun 4, 2024View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Jun 16, 2023Jun 21, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,00011,000Jun 16, 2023Jun 21, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
5,000$22.06$110.3K5,000Jun 8, 2023Jun 9, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,7508,750Jun 17, 2022Jun 21, 2022View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jan 3, 2022Jan 10, 2022View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
35,00035,000Jan 3, 2022Apr 4, 2022View →
Other insiders · CRNX
Loading peer insiders…
About this filer
CIK 0001610381
ROLE
Director
PRIMARY
CRNX
COMPANIES
2
ACTIVE SINCE
Jan 2022
MARKETPEEL · /INSIDER/0001610381DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback